Literature DB >> 15790453

A comparison between different postoperative treatment modalities of uterine carcinosarcoma.

Joseph Menczer1, Tally Levy, Benjamin Piura, Angela Chetrit, Marco Altaras, Mihai Meirovitz, Marek Glezerman, Ami Fishman.   

Abstract

OBJECTIVE: Uterine carcinosarcomas are highly aggressive neoplasms with no established effective adjuvant therapy. The aim of the present study was to compare between the outcome in three medical institutions in each of which a different postoperative treatment modality was preferred, namely, chemotherapy in one, whole pelvic irradiation (WPI) in another, and sequential treatment (i.e., chemotherapy followed by WPI) in the third.
METHODS: The hospital records of all 49 uterine carcinosarcoma patients diagnosed and operated from 1995 to 2003 in the three institutions were reviewed. Non-parametric test was used to compare the median age between the treatment groups. Survival was calculated using the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression model was used to assess the effect of treatment type on survival after adjustment for stage.
RESULTS: Only about half of the patients (51%) had stage I at diagnosis and the majority of the patients (83.7%) had postoperative adjuvant treatment. The overall 5-year survival of the 41 patients that had postoperative treatment was 49.6%. The highest median survival and 5-year survival rate was observed in the sequential treatment group. Controlling for stage, this treatment modality was associated with a significant decrease in mortality of about 80% when compared to postoperative chemotherapy alone, and a non-significant decrease in mortality of about 50% when compared to WPI alone (HR = 0.20; 95% CI 0.04-0.99, P = 0.049 and HR = 0.50; 95% CI 0.1-2.32, P = 0.4, respectively).
CONCLUSIONS: The improved outcome in patients who received postoperative sequential treatment seems to indicate that further exploration of this treatment modality is justified.

Entities:  

Mesh:

Year:  2005        PMID: 15790453     DOI: 10.1016/j.ygyno.2004.12.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.

Authors:  Marco A C Versluis; Cindy Pielsticker; Maaike A van der Aa; Marco de Bruyn; Harry Hollema; Hans W Nijman
Journal:  Oncology       Date:  2018-05-23       Impact factor: 2.935

Review 2.  Review of Recommended Treatment of Uterine Carcinosarcoma.

Authors:  Joseph Menczer
Journal:  Curr Treat Options Oncol       Date:  2015-11

Review 3.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

4.  Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein.

Authors:  Wan-Yee Tang; Retha Newbold; Katerina Mardilovich; Wendy Jefferson; Robert Y S Cheng; Mario Medvedovic; Shuk-Mei Ho
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

Review 5.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

7.  18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.

Authors:  Kung-Chu Ho; Chyong-Huey Lai; Tzu-I Wu; Koon-Kwan Ng; Tzu-Chen Yen; Gigin Lin; Ting-Chang Chang; Chun-Chieh Wang; Swei Hsueh; Huei-Jean Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-19       Impact factor: 9.236

8.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

9.  Carcinosarcomas of the Uterus: Prognostic Factors and Impact of Adjuvant Treatment.

Authors:  Kerri Beckmann; Sudarshan Selva-Nayagam; Ian Olver; Caroline Miller; Elizabeth S Buckley; Kate Powell; Dianne Buranyi-Trevarton; Raghu Gowda; David Roder; Martin K Oehler
Journal:  Cancer Manag Res       Date:  2021-06-10       Impact factor: 3.989

10.  The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma.

Authors:  Hae Jin Park; Hak Jae Kim; Hong-Gyun Wu; Hans Kim; Sung Whan Ha; Soon-Beom Kang; Yong-Sang Song; Noh-Hyun Park; Jae-Won Kim
Journal:  Radiat Oncol J       Date:  2011-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.